Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen
An erratum to this article was published (Diabetes Care, 1 Feb 2026 ↗)
Authors' conclusion
Slower, flexible titration improved adherence and reduced adverse events without compromising efficacy.
Study context
- Population
- Patients with T2D
- Participants
- 104 patients
- Comparison
- Flexible semaglutide titration vs label-recommended titration
Methodological detailsopen-label, pilot
- Open-label
- Pilot
Primary result
As reported in the abstract
Withdrawal due to GI-AEs · 26 weeks
P = 0.005
Further findings
Final doses
- Final doses were similar between groups
HbA1c and BMI changes
- HbA1c and BMI changes were similar between groups
Safety
Nausea
P = 0.051
Asthenia
P = 0.047
Days with nausea
P = 0.017
Original publication
Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen. Diabetes Care. Published 17 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →